News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics completes strategic transition by selling GOLIKE rights outside the U.S. to Nutrisens, focusing on R&D and licensing for commercialized products. Company receives CHF 1.2 million upfront -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE